Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Peerj|April 11, 2017
Prioritisation of structural variant calls in cancer genomesMiika J Ahdesmäki, Brad A Chapman, Pablo Cingolani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2013
Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patientsJustin Guinney, Charles Ferté, Jonathan Dry, et al.
Cancers|November 27, 2021
Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate CancerT Hedley Carr, Carrie Adelman, Alan Barnicle, et al.
The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
Nature Medicine|May 5, 2015
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790MKenneth S Thress, Cloud P Paweletz, Enriqueta Felip, et al.
Oncotarget|December 17, 2017
Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrumDanielle M Greenawalt, Winnie S Liang, Sakina Saif, et al.
The New Zealand Medical Journal|September 15, 2015
Multidisciplinary operating room simulation-based team training to reduce treatment errors: a feasibility study in New Zealand hospitalsJennifer Weller, David Cumin, Jane Torrie, et al.
The Lancet. Oncology|December 8, 2014
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trialAmit M Oza, David Cibula, Ana Oaknin Benzaquen, et al.
Lancet (London, England)|February 24, 2012
A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysisAnthony J Avery, Sarah Rodgers, Judith A Cantrill, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker AssessmentMark Roschewski, Manish R Patel, Patrick M Reagan, et al.
Pageof 7